These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


694 related items for PubMed ID: 31903153

  • 21. Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy.
    Long Y, Tsai WB, Wang D, Hawke DH, Savaraj N, Feun LG, Hung MC, Chen HH, Kuo MT.
    Cancer Lett; 2017 Mar 01; 388():54-63. PubMed ID: 27913198
    [Abstract] [Full Text] [Related]

  • 22. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
    Watanabe S, Shimada S, Akiyama Y, Ishikawa Y, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Yamaoka S, Tanabe M, Tanaka S.
    Int J Cancer; 2019 Jul 01; 145(1):192-205. PubMed ID: 30556125
    [Abstract] [Full Text] [Related]

  • 23. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
    Savaraj N, Wu C, Li YY, Wangpaichitr M, You M, Bomalaski J, He W, Kuo MT, Feun LG.
    Oncotarget; 2015 Mar 20; 6(8):6295-309. PubMed ID: 25749046
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.
    Przystal JM, Hajji N, Khozoie C, Renziehausen A, Zeng Q, Abaitua F, Hajitou A, Suwan K, Want E, Bomalaski J, Szlosarek P, O'Neill K, Crook T, Syed N.
    Cell Death Dis; 2018 Dec 13; 9(12):1192. PubMed ID: 30546006
    [Abstract] [Full Text] [Related]

  • 25. Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes.
    Alexandrou C, Al-Aqbi SS, Higgins JA, Boyle W, Karmokar A, Andreadi C, Luo JL, Moore DA, Viskaduraki M, Blades M, Murray GI, Howells LM, Thomas A, Brown K, Cheng PN, Rufini A.
    Sci Rep; 2018 Aug 14; 8(1):12096. PubMed ID: 30108309
    [Abstract] [Full Text] [Related]

  • 26. Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation.
    Singh PK, Deorukhkar AA, Venkatesulu BP, Li X, Tailor R, Bomalaski JS, Krishnan S.
    Mol Cancer Ther; 2019 Dec 14; 18(12):2381-2393. PubMed ID: 31395686
    [Abstract] [Full Text] [Related]

  • 27. Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells.
    Qiu F, Chen YR, Liu X, Chu CY, Shen LJ, Xu J, Gaur S, Forman HJ, Zhang H, Zheng S, Yen Y, Huang J, Kung HJ, Ann DK.
    Sci Signal; 2014 Apr 01; 7(319):ra31. PubMed ID: 24692592
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents.
    Tsai WB, Long Y, Park JR, Chang JT, Liu H, Rodriguez-Canales J, Savaraj N, Feun LG, Davies MA, Wistuba II, Kuo MT.
    Oncogene; 2016 Mar 31; 35(13):1632-42. PubMed ID: 26096933
    [Abstract] [Full Text] [Related]

  • 32. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
    Fiedler T, Strauss M, Hering S, Redanz U, William D, Rosche Y, Classen CF, Kreikemeyer B, Linnebacher M, Maletzki C.
    Cancer Biol Ther; 2015 Mar 31; 16(7):1047-55. PubMed ID: 25774632
    [Abstract] [Full Text] [Related]

  • 33. Arginine deprivation as a targeted therapy for cancer.
    Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N.
    Curr Pharm Des; 2008 Mar 31; 14(11):1049-57. PubMed ID: 18473854
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
    Yeh TH, Chen YR, Chen SY, Shen WC, Ann DK, Zaro JL, Shen LJ.
    Mol Pharm; 2016 Jan 04; 13(1):262-71. PubMed ID: 26642391
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance.
    Kim Y, Kobayashi E, Kubota D, Suehara Y, Mukaihara K, Akaike K, Ito A, Kaneko K, Chuman H, Kawai A, Kitano S.
    Oncotarget; 2016 Oct 25; 7(43):70832-70844. PubMed ID: 27683125
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 35.